Phase I study of recombinant human endostatin in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3792-3803

  Herbst, Roy S ^a   Hess, Kenneth R ^a   Tran, Hai T ^a   Tseng, Jennifer E ^a   Mullani, Nizar A ^a   Charnsangavej, Chusilp ^a   Madden, Timothy ^a   Davis, Darren W ^a   McConkey, David J ^a   O'Reilly, Michael S ^a   Ellis, Lee M ^a   Pluda, James ^a   Hong, Waun K ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOSTATIN;

ADULT; AGED; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; FEMALE; HUMAN; IMAGING SYSTEM; MALE; PHASE 1 CLINICAL TRIAL; PICHIA PASTORIS; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANGIOGENESIS INHIBITORS; COLLAGEN; COLLAGEN TYPE XVIII; E-SELECTIN; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEMATOLOGIC DISEASES; HUMANS; IMMUNOGLOBULINS; INFUSIONS, INTRAVENOUS; LYMPHOKINES; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037106261     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.061     Document Type: Article

References (36)

1. What is the evidence that tumors are angiogenesis dependent?
2. Tumor angiogenesis
3. Tumor angiogenesis
4. Cancer biology: Invasion and metastasis
5. The implications of angiogenesis for the biology and therapy of cancer metastasis
6. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
7. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
8. Angiostatin and endostatin: Endogenous inhibitors of tumor growth
9. Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the alpha 1(XVIII) collagen gene to mouse chromosome 10 and human chromosome 21
10. Zinc ligand-disrupted recombinant human endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile
11. User's guide: Pharmacokinetic/pharmacodynamic systems analysis software
12. Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis
13. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel chemotherapy (CRx) to CRx alone in patients with stage IIIb/IV NSCLC
14. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU 5416 in patients with solid tumors
15. Antiangiogenesis: Basic principles
16. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancer
17. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
18. Serum endostatin levels in patients with hepatocellular carcinoma
19. Serum endostatin levels are elevated in patients with soft tissue sarcoma
20. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer
21. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma
22. Induction of apoptosis of human endothelial cells by recombinant endostatin: Development of surrogate assay for clinical studies
23. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
24. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model
25. Study of the media's influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial
26. Fractals and cancer
27. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy
28. Angiostatin induces and sustains dormancy of human primary tumors in mice
29. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
30. Vascular targeting and the inhibition of angiogenesis
31. Clinical trial designs for cytostatic agents: Are new approaches needed?
32. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism - The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998
33. Interaction of endostatin with integrins associated with angiogenesis
34. Endostatin binds tropomyosin: A potential modulator of the antitumor activity of endostatin
35. The NC1/endostatin domain of Caenorhabditis elegans type XVIII collagen affects cell migration and axon guidance
36. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin